Abstract

You have accessJournal of UrologyCME1 May 2022PD22-04 IMMEDIATE RADIOTHERAPY VERSUS OBSERVATION IN PATIENTS WITH NODE-POSITIVE PROSTATE CANCER AFTER RADICAL PROSTATECTOMY Christian Schaufler, Sumedh Kaul, Aaron Fleishman, Ruslan Korets, Peter Chang, Andrew Wagner, Simon Kim, Joaquim Bellmunt, Irving Kaplan, Aria F. Olumi, and Boris Gershman Christian SchauflerChristian Schaufler More articles by this author , Sumedh KaulSumedh Kaul More articles by this author , Aaron FleishmanAaron Fleishman More articles by this author , Ruslan KoretsRuslan Korets More articles by this author , Peter ChangPeter Chang More articles by this author , Andrew WagnerAndrew Wagner More articles by this author , Simon KimSimon Kim More articles by this author , Joaquim BellmuntJoaquim Bellmunt More articles by this author , Irving KaplanIrving Kaplan More articles by this author , Aria F. OlumiAria F. Olumi More articles by this author , and Boris GershmanBoris Gershman More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002564.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The optimal management of node-positive (pN1) prostate cancer following radical prostatectomy (RP) remains uncertain. Despite randomized evidence, use of immediate, life-long androgen deprivation therapy (ADT) remains poor, and recent trials of early salvage radiotherapy included only a minority of pN1 patients. We therefore emulated a hypothetical pragmatic trial of immediate (adjuvant) radiotherapy versus observation in men with pN1 prostate cancer. METHODS: Using RADICALS-RT to inform the design of a hypothetical target trial, we identified men aged 50-69 years with pT2-3 Rany pN1 M0, pre-treatment PSA <50 ng/mL prostate cancer in the NCDB from 2006-2015 treated with 60-72 Gy of adjuvant RT (aRT) ± ADT within 26 weeks of RP or observation. After estimating a propensity score for receipt of aRT, we estimated absolute and relative treatment effects using stabilized inverse probability of treatment (sIPW) re-weighting. RESULTS: A total of 3,510 patients were included in the study, of whom 587 (17%) received aRT (73% with concurrent ADT). Median follow-up was 42.3 months, during which time 333 deaths occurred. After sIPW re-weighting, baseline characteristics were well-balanced. Adjusted OS was 94% versus 89% at 5-years and 82% versus 80% at 8-years for aRT versus observation (Figure 1; p=0.12). In IPW-reweighted Cox regression modelling, aRT was associated with a lower risk of all-cause mortality than observation, but this did not reach statistical significance (HR 0.71, p=0.06). In analyses examining heterogeneity of treatment effects, aRT was associated with improved OS only for men with Gleason 8-10 disease (HR 0.59, p=0.01), ³2 positive LNs (HR 0.50, p=0.04 for 2 positive LNs; HR 0.43, p=0.01 for ³3 positive LNs), or negative surgical margins (HR 0.50, p=0.03). CONCLUSIONS: In observational analyses designed to emulate a hypothetical target trial of aRT versus observation in pN1 prostate cancer, aRT was associated with improved OS only for men with Gleason 8-10 disease, ³ 2 positive LNs, or negative surgical margins. Source of Funding: The authors have no funding disclosures © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e403 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Christian Schaufler More articles by this author Sumedh Kaul More articles by this author Aaron Fleishman More articles by this author Ruslan Korets More articles by this author Peter Chang More articles by this author Andrew Wagner More articles by this author Simon Kim More articles by this author Joaquim Bellmunt More articles by this author Irving Kaplan More articles by this author Aria F. Olumi More articles by this author Boris Gershman More articles by this author Expand All Advertisement PDF downloadLoading ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call